Clinical trial sponsor organizations are deploying automated benchtop gene sequencers across regional oncology centers. The shift bypasses centralized reference laboratories, significantly accelerating patient recruitment for targeted therapies.
Operational Timelines
Mean time from biomarker biopsy to trial enrollment has decreased from 21 days to under 96 hours. Rapid trial onboarding critical for aggressive tumor profiles improves protocol compliance and retention rates.
Data Validation Standards
Regulatory agencies demand standardized calibration across decentralized sequencing platforms. Quality assurance frameworks now mandate real-time synthetic control validation for clinical data submissions.